Evidence map›Paper›PMID 41453905›Full record

ArticleNPJ vaccines2025

Influenza vaccination post-COVID-19 expands vaccine-specific effector CD4 T-cells and Tregs under positive influence of host trained innate immunity.

Hima Bindhu, Srabanti Rakshit, Vasista Adiga, Asma Ahmed, Nirutha Chetan Kumar, Maria Macrina, Himanshu Tripathi, Francesca Vanni, Emanuele Montomoli, Sweety Samal and 7 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hima BindhuHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Srabanti RakshitHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Vasista AdigaHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Asma AhmedHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Nirutha Chetan KumarHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Maria MacrinaHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Himanshu TripathiHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Francesca VanniVisMederi Srl, Monteriggioni, Italy.
Emanuele MontomoliVisMederi Srl, Monteriggioni, Italy.
Sweety SamalTranslational Health Science and Technology Institute; NCR Biotech Science Cluster, Faridabad, India.
Sneha RajTranslational Health Science and Technology Institute; NCR Biotech Science Cluster, Faridabad, India.
Preeti VishwakarmaTranslational Health Science and Technology Institute; NCR Biotech Science Cluster, Faridabad, India.
George D SouzaDepartment of Pulmonary Medicine, St. John's Medical College, Bangalore, India.
Shruthi SasidharanDivision of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Mary DiasDivision of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India.
Timothy TreePeter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, Faculty of Life Science & Medicine, King's College, London, UK.
Annapurna VyakarnamHuman Immunology Laboratory, Division of Infectious Diseases, St. John's Research Institute, Bangalore, Karnataka, India. anna.vyakarnam@kcl.ac.uk.

Funding

DBT-BioCARe, Govt of India BT/PR50853/BIC/101/1314/2023Department of Biotechnology (DBT)- INDIGO CONSORTIUM BT/IN/EU-INF/17/GK/2019-20Department of Biotechnology (DBT)- National Institutes of Health (NIH) BT/PR30219/MED/15/189/2018
6 · The paper itself

Abstract

SARS-CoV-2 immunity and innate immune training may influence influenza vaccine immunogenicity. We investigated this in India. Adult volunteers with hybrid SARS-CoV-2 immunity were administered Fluarix

Identifiers

PMID41453905
PMCPMC12789689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.